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Abstract
Background: The standard of care for metastatic gastric cancer (MGC) is systemic chemotherapy
which leads to a median survival of 6-15 months. Survival beyond 3 years is rare. For selected
groups of patients with limited MGC, retrospective studies have shown improved overall survival
following gastrectomy and metastasectomies including peritoneal stripping with continuous
hyperthermic peritoneal perfusion (CHPP), liver resection, and pulmonary resection. Median
survival after liver resection for MGC is up to 34 months, with a five year survival rate of 24.5%.
Similarly, reported median survival after pulmonary resection of MGC is 21 months with long term
survival of greater than 5 years a possibility. Several case reports and small studies have
documented evidence of long-term survival in select individuals who undergo CHPP for MGC.
Design: The GYMSSA trial is a prospective randomized trial for patients with MGC. It is designed
to compare two therapeutic approaches: gastrectomy with metastasectomy plus systemic
chemotherapy (GYMS) versus systemic chemotherapy alone (SA). Systemic therapy will be
composed of the FOLFOXIRI regimen. The aim of the study is to evaluate overall survival and
potential selection criteria to determine those patients who may benefit from surgery plus systemic
therapy. The study will be conducted by the Surgery Branch at the National Cancer Institute (NCI),
National Institutes of Health (NIH) in Bethesda, Maryland. Surgeries and followup will be done at
the NCI, and chemotherapy will be given by either the local oncologist or the medical oncology
branch at NCI.
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Background
Gastric cancer is the fourth most common cancer world-
wide. Approximately, 930,000 people are diagnosed each
year and the annual mortality is close to 700,000 [1]. In
the United States, this year, approximately, 21,500 people
will develop gastric cancer and an estimated 10,880 indi-
viduals will die from the disease [2]. At the time of diag-
nosis, 35% of patients have evidence of distant metastases
including 31% with peritoneal disease, 14% with meta-
static liver disease, and 16% with lung metastases [3-5].
Palliative chemotherapy has been widely used as the treat-
ment of choice for MGC, but only minimal improvements
have been observed. Historical data show that patients
with MGC who received no treatment had median sur-
vival of 3 months, while patients who received modern
regimens had median survivals of 7-15 months, and a 2%
5-year survival [6-10].
One of the newer and more promising chemotherapy
treatments for MGC is the modified FOLFOXIRI regimen
consisting of 5-Fluorouracil, leucovorin, oxaliplatin and
irinotecan [11,12]. Results from two phase II trials using
the FOLFOXIRI regimen were among the best ever
reported for gastric cancer, with overall response rates of
63-66% (CR 2-4% and PR 60-65%), median survival 12-
15 months, and median time to progression 7-10 months.
The most common grade 3/4 toxicities were neutropenia
(12-49% for all cycles), emesis (8-42% for all cycles),
grade 2 neuropathy (10%), grade 3 diarrhea (10%), and
stomatitis (4%). No grade 4 non-hematologic toxicities
were observed.
In regard to locoregional treatments, four separate small
studies concluded that complete removal of both the gas-
tric primary and all visible peritoneal disease combined
with intraperitoneal chemotherapy (CHPP) was associ-
ated with improved survival [13-16]. In the report by
Hirose et al., patients who received a CHPP for peritoneal
recurrences had improved median survival from 6 to 11
months [15].
Surgical resection of metastatic disease for gastric cancer is
not widely performed. We recently performed a critical
review of the literature (Kerkar et al., in preparation) and
identified 19 studies reporting survival rates on a total of
358 patients who underwent liver resections for MGC.
The median of all individual median survivals among
reporting studies was 18 months and median five year
actuarial survival was 24.5% (range: 0-60%). Although
follow up was limited in several studies, 13.4% of patients
were still alive at 5 years. In regard to pulmonary metas-
tases from gastric cancer, 22 publications have reported
on 45 patients who underwent 49 resections of pulmo-
nary MGC following curative resections of primary gastric
malignancies, including patients who have undergone
repeat pulmonary resections as well as combinations of
hepatic and pulmonary resections (Kemp et al, in prepa-
ration). Median overall survival was 21 months [17,18]
with multiple reports of survival of greater than 5 years
and one study reporting a long term survivor alive 7 years
after metastasectomy [19-22].
In light of this retrospective data suggesting that in highly
selected patients with limited MGC an aggressive surgical
approach plus systemic therapy might improve outcomes,
we designed the GYMSSA trial. It is designed to answer the
following questions: Is there a group of patients that
might benefit from this aggressive surgical plus systemic
therapy approach, and if so, how do we choose these
patients while avoiding those who will not benefit?
Methods
Ethical Approval
The GYMSSA trial was approved by the Institutional
Review Board (IRB) of the National Cancer Institute,
National Institutes of Health, Bethesda, Maryland.
Design
This is a randomized controlled trial. The trial schema is
illustrated in Figure 1. The study will be performed at the
Clinical Center of the NIH by the Surgery and Medical
Oncology Branches of NCI in Bethesda, Maryland, USA.
After thorough staging, including laparoscopy and perito-
neal washings, patients will be stratified and randomized
to one of two arms: GYMS (gastrectomy, metastasectomy
plus systemic therapy) vs. SA (systemic therapy alone.)
Stratification and Randomization
Registration of patients onto this study will take place
within 7 days of obtaining patient consent by faxing a
completed eligibility checklist to the Central Registration
Office (CRO) at the Clinical Center/NCI. All patients will
undergo diagnostic laparoscopy with peritoneal washings
to evaluate for occult peritoneal disease and then patients
will be stratified and subsequently randomized by the
CRO to GYMS or SA arm. The CRO will notify the Study
Coordinator of the results of randomization.
Stratification will be done according to the following fac-
tors: site of metastases (liver, lung, and peritoneal disease,
with positive peritoneal washings stratified as peritoneal
disease), time to development of first metastases (less
than 1 year versus greater than 1 year), and previous sys-
temic chemotherapy (specifically given for known gastric
metastases versus standard adjuvant systemic chemother-
apy).
Within 14 days of randomization, patients in the SA arm
will begin chemotherapy treatment with FOLFOXIRI (5-
FU, leucovorin, oxaliplatin and irinotecan) and those inTrials 2009, 10:121 http://www.trialsjournal.com/content/10/1/121
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the GYMSA arm will undergo resection followed by sys-
temic FOLFOXIRI chemotherapy 6-12 weeks after surgery.
As many of the patients referred to this trial will likely
have seen 1st line regimens for metastatic disease, we
noted that oxaliplatin and/or irinotecan were equally
effective in phase-III trials [23] when compared to other
common regimens for gastric cancer. Therefore, patients
will receive the FOLFOXIRI as described by Masi et. al.
from the GONO group [24]. Based on promising results
from recent trials and evidence of an acceptable toxicity
profile compared to the more standard ECF (epirubicin,
cisplatin, and 5-Fluorouracil), we thought that FOLFOX-
IRI, while unusual, might result in improved survivals. We
also felt this line of thought was particularly reasonable
since a majority of our patients will have already seen
ECF.
Statistics
The primary objective of the trial is to determine if there is
a difference in overall survival among patients with lim-
ited gastric cancer metastases who are randomized to
receive systemic therapy alone or gastrectomy, metastasec-
tomy plus systemic therapy.
Based upon published data, patients who would be eligi-
ble for this trial and who receive systemic chemotherapy
alone would be expected to have an estimated 12 month
median overall survival from the date of randomization.
The primary endpoint of this study will be to determine if
the use of gastrectomy, metastasectomy and systemic
chemotherapy will result in an 8 month increase in overall
survival, to a median of 20 months. Patients will be rand-
omized between systemic therapy alone or gastrectomy,
metastasectomy and systemic chemotherapy and fol-
Trial Schema Figure 1
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lowed for overall survival. Stratification will adjust for site
of metastases (liver, peritoneal and lung), disease-free
interval (DFI), and previous systemic therapy for gastric
metastases. Note: positive peritoneal washings will be
stratified as peritoneal disease. Kaplan-Meier curves and a
two-tailed log-rank test will be the primary analysis meth-
ods. Assuming exponential overall survival curves, the
hazard rate for the systemic therapy is 0.0578, or approx-
imately a 5.8% probability of death each month when the
median survival is 12 months. If we assume that the sur-
gery plus systemic therapy arm has a median overall sur-
vival of 20 months, this corresponds to a hazard rate of
0.0347, and the resulting hazard ratio for the comparison
of the two overall survival curves would be 1.67. To com-
pare these curves and detect a difference with a 0.05 two-
tailed log-rank test, a total of 68 evaluable subjects per
arm (136 total) will need to be enrolled over a six year
period and followed for an additional two years from the
date of entry of the last patient, with 121 total deaths, in
order to have 80% power to compare the curves.
Progression free survival will also be evaluated using Kap-
lan-Meier curves, and a two-tailed log rank test, as a sec-
ondary endpoint. In addition, a prognostic factor
evaluation using Cox proportional hazards modeling will
take place after the study has concluded in order to iden-
tify factors that are associated with survival or progression
free survival in patients randomized to treatments on this
trial; this will also be interpreted as a secondary endpoint.
Quality of life parameters will be measured using evalua-
tions designed for patients with gastric cancer (FACT-Ga,
EORTC QLQ-STO22, SROTC QLQ-C30) [25-28] and will
be compared using the Wilcoxon rank-sum method
between the two study arms at multiple individual time
points to determine the differences between the two arms
as well as a change from baseline. This evaluation will be
considered secondary, and p-values resulting from the
analysis will be presented without adjustment for multi-
ple comparisons, but in the context of the number of tests
evaluated.
It is expected that 24 patients per year can be accrued onto
this trial, and thus accrual will be completed in approxi-
mately 6 years. Allowing for a very small number of ine-
valuable patients, the accrual ceiling will be set at 140
patients.
Data Monitoring
The study will be monitored by the NCI Center for Cancer
Research Data Safety and Monitoring Board (DSMB) on
an annual basis to evaluate the safety of the two arms. All
adverse events will be recorded. For toxicities possibly
attributed to the therapy provided on that arm, serious
adverse events (grade 3 toxicities or greater) will be
reported according to type of toxicity and maximal grade
noted per patient. Comparisons will be made between the
two arms using Cochran-Armitage tests for trend, or other
appropriate methods, to determine if there is increased
toxicity associated with either arm.
In addition, at the first DSMB meeting held following the
point at which half of the required total subjects have
been enrolled (68 total), a single evaluation for futility
will be undertaken. Evaluations for better than expected
efficacy will also be made annually, beginning after half
the subjects have been enrolled.
Inclusion and Exclusion Criteria
Inclusion Criteria
• Histologically or cytologically confirmed gastric ade-
nocarcinoma with or without prior resection of the
primary or metastatic disease
￿ Limited metastatic disease that is measurable by CT,
mandatory PET scan and/or MRI:
- Esophageal invasion <4 cm that does not require tho-
racotomy (Seiwert II and III lesions)
- Hepatic metastases (unilateral or bilateral, ≤ 5
lesions, ≤ 15 cm total diameter)
- Primary peritoneal metastases (small disease load, ≤
P2 disease) without clinically significant ascites or
intestinal obstruction
- Lung metastases (≤ 3 unilateral/bilateral, 9 cm total
diameter)
- Patients who present with both hepatic and perito-
neal metastases must have no evidence of extensive
para-aortic/retro-pancreatic lymph node metastases
￿ All disease should be deemed resectable to negative
margins (NED) based on imaging studies
￿ Patients with or without prior chemotherapy treat-
ments for metastatic disease will be eligible
￿ Age greater than 18 years
￿ Clinical performance status of ECOG ≤ 2
￿ Life expectancy of greater than three months
￿ No history of prior/other malignancies within the 2
years prior to enrollment with the exception of basal
cell carcinomaTrials 2009, 10:121 http://www.trialsjournal.com/content/10/1/121
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￿ Laboratory parameters within acceptable limits to
undergo surgical resection and/or systemic chemo-
therapy
Exclusion Criteria
￿ Prior treatment with FOLFOXIRI (treatment with
any of the components as separate regimens is allow-
able)
￿ Patients with both pulmonary and peritoneal metas-
tases
￿ Active systemic infections, coagulation disorders or
other major medical illnesses (cardiovascular, respira-
tory or immune system, myocardial infarction, cardiac
arrhythmias, obstructive or restrictive pulmonary dis-
ease)
￿ Brain metastases or a history of brain metastases
￿ Childs B or C cirrhosis or with evidence of severe
portal hypertension by history, endoscopy, or radio-
logic studies
￿ Weight less than 40 kg
￿ Significant ascites, greater than 1000 cc in the
absence of peritoneal disease
￿ History of congestive heart failure and/or an LVEF <
40%
￿ Significant COPD or other chronic pulmonary
restrictive disease with PFT's indicating an FEV1 less
than 50% or a DLCO less than 40% predicted for age
￿ Concomitant medical problems that would place
the patient at an unacceptable risk for a major surgical
procedure
Intervention
GYMS Arm
All patients randomized to the GYMS arm will undergo
surgical resection of their primary and/or metastatic
tumors within 14 days of randomization. Patients will
undergo surgery only at the Surgery Branch, NCI with the
goal of resection of all visible metastases to leave patients
with no evidence of disease.
Patients with proximal gastric lesions will undergo total
gastrectomy with a 2-4 cm esophageal margin, those with
cardiac or fundic tumors with undergo total gastrectomy,
and those with distal lesions will undergo a radical subto-
tal gastrectomy. All procedures will include a modified D2
lymphadenectomy and a Roux-en-Y reconstruction.
Pulmonary and hepatic metastasectomies will be per-
formed in a standard fashion at the discretion of the
attending thoracic or surgical oncologist. Patients who
have peritoneal disease will undergo complete peritonec-
tomy and CHPP with intravenous 5-FU/leucovorin and
intraperitoneal oxaliplatin. Patients who present with
intrabdominal disease without peritoneal involvement
will undergo a limited peritonectomy followed by CHPP
with intravenous 5-FU/leucovorin and intraperitoneal
oxaliplatin.
Patients who present with synchronous intrabdominal
metastatic disease (hepatic or peritoneal) at time of initial
diagnosis will undergo a gastrectomy and appropriate
metastasectomy. For patients with synchronous pulmo-
nary metastases, a decision will be made by the thoracic
and surgical oncologist as to the optimal timing of gastrec-
tomy and metastasectomy (synchronous or staged resec-
tions) with a delay of no more than 8 weeks between
procedures.
All patients must begin systemic FOLFOXIRI chemother-
apy within 8 weeks after surgical resection.
SA Arm
Patients randomized to the systemic therapy arm (SA) will
receive systemic FOLFOXIRI chemotherapy either by their
home medical oncologist or by the Medical Oncology
Branch, NCI. Only palliative surgery will be allowed as per
standard of care for issues such as obstruction, bleeding
and/or intractable pain. No crossover will be allowed.
Data Collection and Evaluation
Data will be collected using the NCI C3D web based data
collection system.
Baseline history and physical examinations, laboratory
studies, radiological imaging, and quality of life question-
naires will be obtained for patients on both arms. Addi-
tional testing will be performed prior to treatment as
dictated by patient characteristics.
Following randomization, followup will be every 2
months during chemotherapy, and then every 3 months
for the first 2 years, every 6 months for the subsequent 3
years, and yearly thereafter. Follow-up will consist of
interval history and physical examination, laboratory
studies, radiological imaging, and quality of life question-
naires.
Lesions will be evaluated using the RECIST criteria. The
duration of overall response will be measured from the
time measurement criteria are met for partial response
(PR) or complete response (CR), until the first date that
recurrent or progressive disease is objectively documentedTrials 2009, 10:121 http://www.trialsjournal.com/content/10/1/121
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(taking as reference for progressive disease the smallest
measurements recorded since the treatment started).
The duration of overall complete response will be meas-
ured from the time that measurement criteria are first met
for CR until the first date that recurrent disease is objec-
tively documented. This study will utilize common termi-
nology criteria for toxicity and adverse event reporting
(version 4.0; http://ctep.info.nih.gov).
Safety and Monitoring Plan
Careful evaluation to ascertain the toxicity and clinical
response will be performed. The principal investigator
will monitor the data and toxicities in order to identify
trends quarterly. The Principal Investigator will be respon-
sible for revising the protocol as needed to maintain
safety. The NCI IRB will review submitted adverse events
monthly to also evaluate trends and will require a follow
up plan from the Principal Investigator whenever a trend
is identified.
The trial will be monitored at least annually by the NCI
DSMB. Interim outcome results will not be revealed to the
investigators of the trial; results will be presented to the
investigators prior to final accrual only if the DSMB rec-
ommends early termination of the trial. Until 68 patients
have been randomized, only toxicity and adverse events
will be examined at each review. Once 68 patients have
been randomized, interim evaluations will be performed
to determine whether there is sufficient evidence to termi-
nate accrual because of a better than expected improve-
ment in overall survival. At the first such review of
outcomes, a single evaluation for futility will also be per-
formed.
Informed Consent
All patients are thoroughly screened prior to initial con-
sultation at the NIH. During the initial consultation, the
patient, along with family members, is presented a forth-
right and detailed overview of the treatment option avail-
able to them at the NIH. The experimental nature of the
treatment, its theoretical advantages and disadvantages,
and an overview of the operative procedure and antici-
pated convalescence are presented. The fact that the
patient may undergo an operative procedure in order to
receive therapy without any assurance of benefit, the
aggressive nature of the treatment, and the likelihood of
serious or potentially life-threatening complications are
presented. The Informed Consent document is given to
the patient and they are asked to review it, make notes,
and follow-up with a phone call to the physician or nurse
investigator in order to have any additional questions
answered prior to considering treatment on protocol. The
research nurse, Principal Investigator, or designee is
responsible for obtaining consent from the patient upon
admission. The signed consent will be verified by the phy-
sician responsible for the care of the patient. Patients are
free to withdraw from the study at any time without any
obligation.
Endpoints/Follow-up of Study
Primary Objective
￿ Determine whether a therapeutic approach that
includes gastrectomy and/or metastasectomy plus sys-
temic therapy is superior to the standard of care
approach that includes systemic therapy alone in
terms of over-all survival for patients who present with
limited metastatic gastric cancer.
Secondary Objectives
￿ Compare progression free survival between the two
study arms
￿ Analyze prognostic factors and generate potential
selection criteria for patients who present with limited
gastric cancer metastases that might benefit from gast-
rectomy and/or metastasectomy plus systemic ther-
apy.
￿ Determine if surgical resection impacts the dosing
and duration of subsequent chemotherapy adminis-
tration
￿ Compare quality of life (QOL) parameters between
the two study groups. We will use tools specifically
developed for assessment of QOL in gastric cancer
patients: FACT-Ga, EORTC QLQ-STO22 and the
SROTC QLQ-C30 [25-28].
￿ Determine and compare patterns of disease recur-
rence between the two therapeutic approaches and
their clinical implications.
Discussion
Overall, gastric cancer is the 14th most common cancer in
the United States, and accounts for 1.5% of all new diag-
noses and 5.2% of all cancer deaths [29]. Long-term sur-
vival for patients with metastatic gastric cancer is dismal,
and any improvement in overall survival will be a signifi-
cant advance. Over the past several decades, improve-
ments in the understanding of anatomy, physiology,
perioperative care, and surgical technique have reduced
operative morbidity and mortality for major resections
such as hepatectomies, thoracotomies, and peritoneal
stripping to less than 4% [30]. Additionally, the latest tri-
als utilizing the FOLFOXIRI chemotherapeutic regimen
have demonstrated improvements in survival for patients
with MGC without any additional major grade 4 non-
hematologic toxicities [11,12].Trials 2009, 10:121 http://www.trialsjournal.com/content/10/1/121
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The optimal treatment for patients with MGC is not
known. The benefit of gastrectomy and metastasectomy
plus systemic chemotherapy versus systemic chemother-
apy alone has not been studied. This trial will either help
validate or reject the notion based on retrospective data
that aggressive surgical resections in combination with
systemic chemotherapy might improve outcomes in met-
astatic gastric cancer.
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